---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-024061"
form_type: "8-K"
ticker: "BTCY"
cik: "0001630113"
company_name: "BIOTRICITY INC."
filed_at: "2025-11-18T23:59:59+00:00"
generated_at: "2026-05-16T18:48:15.596525+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Biotricity Q2 FY2026 revenue up 19% to $3.9M; net loss narrows 53% to $0.77M

## Summary
- Revenue $3.9M (+19% YoY); gross margin 81.9% vs 75.3% prior year.
- Net loss $0.77M ($0.03/sh) vs $1.7M ($0.07/sh), a 53% improvement.
- Recurring TaaS technology fees $3.5M, 88.7% of total revenue.
- Regulatory progress in Canada, Saudi Arabia, and Argentina; GPOs covering 90% of U.S. hospitals.
- CEO cites AI-driven automation and Biocore Pro adoption as growth drivers.

## SEC filing metadata
- accession: 0001493152-25-024061
- form_type: 8-K
- ticker: BTCY
- cik: 0001630113
- company_name: BIOTRICITY INC.
- filed_at: 2025-11-18T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1630113/000149315225024061/0001493152-25-024061-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1630113/000149315225024061/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-024061
- JSON: https://secwatch.observer/filing/0001493152-25-024061.json
- Plain text: https://secwatch.observer/filing/0001493152-25-024061.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.